Cardinal Health (CAH) reported a solid start to fiscal 2025, with total revenue of $52 billion, reflecting a 4% decline largely due to a significant customer transition. However, excluding this transition, revenue surged by 15%, driven by strong demand in the Pharmaceutical and Specialty Solutions segment, which saw a 16% increase in segment profit. The company also raised its fiscal 2025 EPS guidance to a range of $7.75–$7.90, citing improved expectations in its Pharma segment.

The financial results underscore Cardinal Health’s resilience amid operational challenges, particularly in its Global Medical Products and Distribution (GMPD) segment, where profit outlooks were tempered by rising health and welfare costs. Despite these headwinds, management remains optimistic about long-term growth, particularly with the announced $1.1 billion acquisition of Integrated Oncology Network aimed at bolstering its specialty offerings.

Investors should note the upward revision in EPS and free cash flow guidance, which reflects Cardinal Health’s strong operational execution and strategic focus on enhancing its portfolio, even as it navigates short-term challenges in the GMPD segment.

Source: fool.com